LAUSR

Introduction There is an ongoing debate as to the role of acute SARS-CoV-2 infection on asthma exacerbation, and its long-term impact on the lung function of individuals with asthma. In contrast, the potential impact of COVID -19 vaccination on asthma is entirely unexplored. Case Study We are shedding light on this critical topic by examining a challenging case of severe asthma exacerbation that a 28-year-old female patient developed after receiving two doses of mRNA-based vaccine BNT162b2 (Pfizer-BioNTech) at our Hospital, IRCCS Policlinico San Matteo of Pavia, in Northern Italy. The patient is a fourth year resident at the hospital, and like all health care workers at the facility, has been vaccinated since early 2021. She was an occasional smoker with a 10-year history of asthma and seasonal allergic rhinitis. She also tested negative for SARS-CoV-2 on several negative molecular swabs and serology tests. Results After receiving the second vaccine dose, she started experiencing a worsening of respiratory symptoms. Following several episodes, and a severe asthma attack, the patient required treatment with mepolizumab, a biologic drug [interleukin-5 (IL-5)] antagonist monoclonal antibody. Conclusion This single case study is insufficient to draw conclusions about the association between asthma exacerbation and the COVID-19 vaccine. While the cause-effect link between vaccination against SARS-CoV-2 and worsening of asthmatic disease might only be suggested, we consider the present case as a valuable prompt for further investigations. This is particularly true from the perspective of mass vaccination of adolescents and children currently underway across the globe.